Fulcrum Asset Management LLP Purchases 18,236 Shares of Viking Therapeutics, Inc. $VKTX

Fulcrum Asset Management LLP lifted its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 118.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 33,569 shares of the biotechnology company’s stock after purchasing an additional 18,236 shares during the period. Fulcrum Asset Management LLP’s holdings in Viking Therapeutics were worth $1,068,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of VKTX. Seven Fleet Capital Management LP purchased a new position in Viking Therapeutics in the second quarter valued at $251,884,000. BlackRock Inc. acquired a new stake in Viking Therapeutics in the second quarter valued at $241,458,000. ADAR1 Capital Management LLC purchased a new stake in Viking Therapeutics during the 2nd quarter worth about $22,393,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Viking Therapeutics during the 2nd quarter worth about $20,699,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Viking Therapeutics by 18.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 542,516 shares of the biotechnology company’s stock worth $17,653,000 after buying an additional 82,941 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Trading Down 0.8%

NASDAQ VKTX opened at $28.44 on Thursday. The firm’s fifty day moving average price is $29.54 and its 200 day moving average price is $32.20. Viking Therapeutics, Inc. has a 12 month low of $23.82 and a 12 month high of $43.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.27 and a quick ratio of 7.27. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of -5.27 and a beta of 0.79.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.49). During the same quarter in the previous year, the firm earned ($0.81) EPS. On average, sell-side analysts expect that Viking Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Viking Therapeutics in a research report on Tuesday, September 22nd. The Goldman Sachs Group reissued a “neutral” rating and set a $34.00 target price on shares of Viking Therapeutics in a research report on Thursday, October 29th. HC Wainwright restated a “buy” rating on shares of Viking Therapeutics in a research note on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a report on Thursday, October 15th. Finally, Oppenheimer set a $120.00 price target on Viking Therapeutics in a report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.36.

About Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company’s pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.